Unicycive(UNCY) - 2024 Q1 - Quarterly Results

– On Track to Provide Topline Data from the Ongoing Pivotal Clinical Trial with Oxylanthanum Carbonate (OLC) in Q2 2024 – Exhibit 99.1 Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update – Multiple Presentations on OLC and UNI-494 at Prominent, Upcoming Medical Meetings – LOS ALTOS, Calif., May 13, 2024 – Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the "Company" or "Unicycive"), a clinical- stage biotechnology company developing therapies for patients with kidney disease, ...